Figure 1.

Correlations between baseline glycated hemoglobin (HbA1c) and change in HbA1c at 6 months. The patients who did not adjust their antidiabetic agents except for switching their dipeptidyl peptidase-4 inhibitor (DPP4i) to empagliflozin were grouped as responders (emp.r) and non-responders (emp.nr) according to the change in HbA1c at 6 months. The remaining patients continued taking DPP4i (nochange). The scatterplots and regression line (95% CI) are stratified by the three groups. The correlations were analyzed using Spearman’s correlation. The responders in the switched-to-empagliflozin had a significant negative correlation (rho=-0.537, P<.001), which remained significant after adjusting for BMI, age, gender, and serum creatinine (rho=-0.577, P<.001).